TScan Therapeutics (NASDAQ:TCRX) Issues Earnings Results

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02, Zacks reports. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The company had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.62 million.

TScan Therapeutics Stock Performance

NASDAQ TCRX traded down $0.07 during trading hours on Friday, hitting $1.24. 311,346 shares of the stock were exchanged, compared to its average volume of 363,115. The company has a market cap of $70.17 million, a price-to-earnings ratio of -1.17 and a beta of 1.06. TScan Therapeutics has a 12-month low of $1.02 and a 12-month high of $9.69. The stock has a 50-day moving average of $1.43 and a 200 day moving average of $2.60. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TCRX. Wedbush restated an "outperform" rating and issued a $7.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, May 6th. Morgan Stanley reaffirmed an "overweight" rating and issued a $10.00 target price on shares of TScan Therapeutics in a report on Friday, March 14th. Needham & Company LLC reaffirmed a "buy" rating and issued a $9.00 target price on shares of TScan Therapeutics in a report on Tuesday, April 8th. Barclays reduced their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Finally, HC Wainwright reduced their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, TScan Therapeutics presently has an average rating of "Buy" and an average target price of $7.80.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TScan Therapeutics stock. Goldman Sachs Group Inc. increased its position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 6.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 170,349 shares of the company's stock after purchasing an additional 9,676 shares during the period. Goldman Sachs Group Inc. owned approximately 0.30% of TScan Therapeutics worth $235,000 as of its most recent SEC filing. Institutional investors and hedge funds own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.